XenoGesis: Sygnature Discovery snaps up fellow BioCity firm

Nottingham-based Sygnature Discovery, the independent integrated drug discovery and pre-clinical services provider, has acquired XenoGesis. The acquisition significantly expands Sygnature’s DMPK capabilities and expertise, with XenoGesis the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation.